Nathaniel Catron
12Patents
4h-index
22Co-inventors
52Inventor score
Filing activity: Apr 29, 2010 → Nov 8, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8722657B2 | Salts and crystalline forms of an apoptosis-inducing agent | Human Necessities | 13 | Active |
| US9006247B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 9 | Active |
| US9403822B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 7 | Active |
| US10213433B2 | Solid dispersions containing an apoptosis-inducing agent | Emerging Cross-Sectional Technologies | 6 | Active |
| US8927009B2 | ABT-263 capsule | Human Necessities | 2 | Active |
| US8513243B2 | ABT-263 crystalline forms | Human Necessities | 2 | Active |
| US9238649B2 | Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Human Necessities | 2 | Active |
| US9840502B2 | Salts and crystalline forms of an apoptosis-inducing agent | Human Necessities | 1 | Active |
| US8362013B2 | Salt of ABT-263 and solid-state forms thereof | Human Necessities | 1 | Active |
| US8362014B2 | ABT-263 crystalline forms | Human Necessities | 1 | Active |
| US8728516B2 | Stabilized lipid formulation of apoptosis promoter | Human Necessities | 0 | Active |
| US10730873B2 | Salts and crystalline forms of an apoptosis-inducing agent | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.